University of Houston: Study Identifies Potential Treatment Target for Prostate Cancer Resistant to Hormone Therapy
June 13, 2023
June 13, 2023
HOUSTON, Texas, June 13 (TNSjou) -- The University of Houston issued the following news release:
Prostate cancer is the most-commonly diagnosed malignancy and the second leading cause of cancer death among men in the United States. In its ever-indelicate world, the stubborn disease can continue to grow even when the amount of testosterone in the body is reduced to very low levels, thus earning the clumsy name: castrate-resistant prostate cancer (CRPC). It poses a major clinical chal . . .
Prostate cancer is the most-commonly diagnosed malignancy and the second leading cause of cancer death among men in the United States. In its ever-indelicate world, the stubborn disease can continue to grow even when the amount of testosterone in the body is reduced to very low levels, thus earning the clumsy name: castrate-resistant prostate cancer (CRPC). It poses a major clinical chal . . .